Abstracts tagged "gout"

Abstract Number: 2896 • 2017 ACR/ARHP Annual Meeting
Human Cartilage Influences the Crystallization of Monosodium Urate; Understanding the Link between Gout and Osteoarthritis
Ashika Chhana¹, Bregina Pool², Ally Choi¹, Ryan Gao¹, Mark Zhu¹, Jillian Cornish², Jacob Munro³ and Nicola Dalbeth⁴, ¹Medicine, University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Orthopaedics, Auckland City Hospital, Auckland, New Zealand, ⁴University of Auckland, Auckland, New Zealand
Background/Purpose: Monosodium urate (MSU) crystal deposition and gout flares frequently affect joints that have been damaged or are affected by osteoarthritis. The aim of…
Abstract Number: 60 • 2017 ACR/ARHP Annual Meeting
Low and Moderate Intensity Exercise Suppresses Inflammatory Responses in an Acute Mouse Model of Gout and Suggests Therapeutic Efficacy
Nicholas A. Young¹, Kyle Jablonski², Juhi Sharma¹, Evelyn Thomas¹, Brian Snoad¹, Jeffrey Hampton³, Wael Jarjour¹ and Naomi Schlesinger⁴, ¹Department of Internal Medicine, Division of Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ²The Ohio State University Wexner Medical Center, Columbus, OH, ³Immunology and Rheumatoloty, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Medicine, Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Little is known regarding the potential benefits of exercise on managing acute gout. Consequently, recent clinical practice guidelines released by the American College of…
Abstract Number: 1121 • 2017 ACR/ARHP Annual Meeting
Allopurinol Treatment for Gout: How Long to Reach Serum Urate Goal?
Jean J. Lim^1,2, An-Chen Fu², Jami Giordano², David S. Reasner² and Douglas C.A. Taylor², ¹Tufts University School of Medicine, Botson, MA, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Urate-lowering therapy (ULT) is essential in chronic gout management. For decades, allopurinol has remained the most frequently prescribed ULT. Reaching a goal of serum…
Abstract Number: 2071 • 2017 ACR/ARHP Annual Meeting
A Novel Selective URAT1 Inhibitor, Tei-a, with Potent Uricosuric Property
Johji Nomura¹, Yoshimasa Takahashi², Kumiko Aoki², Naoki Hase² and Tsunefumi Kobayashi², ¹Teijin Institute for Bio-medical Research, TEIJIN PHARMA LIMITED, Tokyo, Japan, ²TEIJIN PHARMA LIMITED, Tokyo, Japan
Background/Purpose: Hyperuricemia, abnormally elevated level of serum uric acid, is associated with gout as well as other diseases including metabolic syndrome, hypertension, diabetic kidney disease.…
Abstract Number: 2950 • 2017 ACR/ARHP Annual Meeting
Validation of a Definition for Flare in Patients with Established Gout
Angelo L. Gaffo¹, Nicola Dalbeth², Kenneth Saag³, Jasvinder A. Singh⁴, Elizabeth J. Rahn¹, Amy S. Mudano⁵, Yi-Hsing Chen⁶, Ching-Tsai Lin⁷, Sandra Bourke², Worawit Louthrenoo⁸, Janitzia Vazquez-Mellado⁹, Hansel Hernández-Llinas¹⁰, Tuhina Neogi¹¹, Ana Beatriz Vargas-Santos¹², Geraldo Castelar-Pinheiro¹³, Rodrigo B. Chaves-Amorim¹³, Till Uhlig¹⁴, Hilde B Hammer¹⁴, Maxim Eliseev¹⁵, Fernando Perez-Ruiz¹⁶, Lorenzo Cavagna¹⁷, Geraldine M. McCarthy¹⁸, Lisa K. Stamp¹⁹, Martijin Gerritsen²⁰, Viktoria Fana²¹, Francisca Sivera²² and William J. Taylor²³, ¹Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Auckland, Auckland, New Zealand, ³Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Taichung Veterans General Hospital, Taichung, Taiwan, ⁷Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ⁸Div of Rheumatology, Dept of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁹Rheumatology, Hospital General de Mexico, Mexico City, Mexico, ¹⁰Hospital General de Mexico, Mexico City, Mexico, ¹¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ¹²Internal Medicine Department, Division of Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹³Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil, ¹⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁵V. A. Nasonova Research Institute of Rheumatology, Moscow, Russian Federation, ¹⁶Servicio de Reumatología, Vizcaya, Spain, ¹⁷Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ¹⁸Div of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, ¹⁹University of Otago, Christchurch, New Zealand, ²⁰Westfries Gasthuis, Hoorn, Netherlands, ²¹Center for Rheumatology and Spine Diseases, Rigshospitalet , Glostrup, Copenhagen Center for Arthritis Research (COPECARE), Copenhagen, Denmark, ²²Sección de Reumatología, Hospital General Universitario de Elda., Elda, Spain, ²³University of Otago, Wellington, New Zealand
Background/Purpose: A standardized validated definition for gout flares (or attacks) is not available. Two provisional definitions published in 2012 were based on patient-reported elements (patient-defined…
Abstract Number: 76 • 2017 ACR/ARHP Annual Meeting
TNF-α Potentiates Uric Acid-Induced Interleukin-1β Secretion in Human Neutrophils
Shuzo Sato¹, Makiko Yashiro¹, Tomoyuki Asano¹, Tomohiro Koga², Eiji Suzuki¹, Hiroko Kobayashi¹, Hiroshi Watanabe¹ and Kiyoshi Migita³, ¹Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Fukushima Medical University School of Medicine, Fukushima, Japan
Background/Purpose: Gout is an inflammatory arthropathy due to the deposition of uric acid (monosodium urate: MSU) crystals in synovial tissue. MSU leads to activate nucleotide-binding…
Abstract Number: 1122 • 2017 ACR/ARHP Annual Meeting
Prevalence of Chronic Kidney Disease and Uncontrolled Serum Uric Acid Levels in US Adult Gout Population: Results from the National Health and Nutrition Examination Survey 2007–2012
Jean J. Lim^1,2, An-Chen Fu², David S. Reasner² and Douglas C.A. Taylor², ¹Tufts University School of Medicine, Botson, MA, ²Ironwood Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Gout is the most common form of inflammatory arthritis, mainly caused by elevated serum uric acid (sUA) levels. The American College of Rheumatology guidelines…
Abstract Number: 2072 • 2017 ACR/ARHP Annual Meeting
A Pharmacokinetic and Pharmacodynamic Evaluation of URC102, a Potent and Selective Inhibitor of URAT1, after Single and Multiple Oral Administrations in Healthy Volunteers
Hyun A Lee¹, Sang-In Park¹, Seonghae Yoon², Makoto Onohara³, Jeongeun Choi⁴, Kyung-Sang Yu¹ and Howard Lee¹, ¹Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea, Republic of (South), ²Clinical Trials Center, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ³Science and Strategy, Translational Clinical Research, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan, ⁴JW Pharmaceutical Corporation, Seoul, Korea, Republic of (South)
Background/Purpose: URC102, a novel and potent inhibitor of human uric acid transporter 1 (hURAT1), is currently under clinical development to treat patients with gout. In…
Abstract Number: 193 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Verinurad, a Selective Uric Acid Reabsorption Inhibitor, in Healthy Japanese Male Subjects
Michael Gillen¹, Jeffrey N. Miner² and Shakti Valdez³, ¹AstraZeneca, Gaithersburg, MD, ²Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: This was a Phase 1, randomized, single-blind, placebo-controlled study (. Panels of 8 Japanese male subjects were randomized in a 3:1 ratio to receive…
Abstract Number: 224 • 2016 ACR/ARHP Annual Meeting
Patient Perception of Gout Flares As a Measure of Outcome: Results from an International Study
Angelo L. Gaffo¹, Nicola Dalbeth², Kenneth G. Saag³, Jasvinder Singh³, Elizabeth J. Rahn¹, Amy S. Mudano³, Tuhina Neogi⁴, Lorenzo Cavagna⁵, Yi-Hsing Chen⁶, Ching-Tsai Lin⁷, Worawit Louthrenoo⁸, Geraldo Castelar-Pinheiro⁹, Fernando Perez-Ruiz¹⁰, Janitzia Vazquez-Mellado¹¹, Maxim Eliseev¹², Lisa K. Stamp¹³ and William Taylor¹⁴, ¹Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²University of Auckland, Auckland, New Zealand, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Boston University School of Medicine, Boston, MA, ⁵Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ⁶Taichung Veterans General Hospital, Taichung, Taiwan, ⁷Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan, ⁸Div of Rheumatology, Dept of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, ⁹Universidade do Estado do Rio de Janeiro - UERJ, Rio de Janeiro, Brazil, ¹⁰Servicio de Reumatología, Vizcaya, Spain, ¹¹Rheumatology, Hospital General de México, Mexico City, Mexico, ¹²Research Institute of Rheumatology of Russia, Moscow, Russian Federation, ¹³University of Otago, Christchurch, New Zealand, ¹⁴University of Otago, Wellington, New Zealand
Patient Perception of Gout Flares as a Measure of Outcome: Results from an International Study Background/Purpose: Attacks (flares) are one of the primary manifestations of…
Abstract Number: 2285 • 2016 ACR/ARHP Annual Meeting
12/15-Lipoxygenase Inhibition By ML351 Protects Against Uric Acid Crystal-Induced Acute Arthritis in Mice
Roxana Coras¹, Alex Stubelius², Oswald Quehenberger³ and Monica Guma¹, ¹Medicine, UCSD, La Jolla, CA, ²Skaggs School of Pharmacy and Pharmaceutical Sciences, UCSD, La Jolla, CA, ³Pharmacology, UCSD, La Jolla, CA
Background/Purpose: Treatment of acute gout involves the use of NSAIDs, colchicine or corticosteroids. Unfortunately, co-morbid conditions such as chronic kidney disease, peptic ulcer disease and…
Abstract Number: 194 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects with Gout
Jesse Hall¹, Michael Gillen², Xiaojuan Yang¹, Sha Liu¹, Susan Walker¹, Vicki Clauson¹ and Martin Kankam³, ¹Ardea Biosciences, Inc., San Diego, CA, ²AstraZeneca, Gaithersburg, MD, ³Vince and Associates Clinical Research, Inc.,, Overland Park, KS
Background/Purpose: Verinurad (RDEA3170) is a novel selective uric acid reabsorption inhibitor in clinical development for the treatment of hyperuricemia and gout. This Phase 1, single-blind,…
Abstract Number: 225 • 2016 ACR/ARHP Annual Meeting
Patterns of Joint Involvement in Gout Flares
Ana Beatriz Vargas-Santos¹, Yuqing Zhang², Na Lu¹, Nicola Dalbeth³, William J. Taylor⁴, Jaap Fransen⁵, Tim Jansen⁶, H. Ralph Schumacher Jr.⁷ and Tuhina Neogi¹, ¹Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology and Training Unit, Boston University School of Medicine, Boston, MA, ³Department of Medicine, University of Auckland, Auckland, New Zealand, ⁴Department of Medicine, University of Otago, Wellington, New Zealand, ⁵Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ⁶VieCuri Medical Center, Venlo, Netherlands, ⁷Medicine, Rheumatology, U Penn & VA Med Ctr, Philadelphia, PA
Background/Purpose: Gout flares are the most common manifestations of gout. Awareness of possible disease presentations beyond the traditionally recognized podagra is essential for accurate and…
Abstract Number: 2289 • 2016 ACR/ARHP Annual Meeting
Obesity and Echocardiographic Changes in the Different Stages of Gout
Rada Gancheva¹, Atanas Kundurdjiev², Mariana Ivanova¹, Todor Kundurzhiev³ and Zlatimir Kolarov¹, ¹Medical Faculty, Medical University, University Hospital "St. Iv. Rilski", Clinic of Rheumatology, Sofia, Bulgaria, ²Medical Faculty, Medical University, University Hospital "St. Iv. Rilski", Clinic of Nephrology, Sofia, Bulgaria, ³Medical University, Faculty of Public Health, Sofia, Bulgaria
Background/Purpose: Studies on gout and its stages as a cardiovascular (CV) risk factor are few and with contradictory results. We compared echocardiographic parameters, known as…
Abstract Number: 195 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamics, Pharmacokinetics, and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone and Verinurad Alone in Japanese Adults with Gout or Asymptomatic Hyperuricemia: A Phase 2a, Open-Label Study
Masanari Shiramoto¹, Masatoshi Sugeno², Sha Liu³, Zangong Shen³ and Jesse Hall³, ¹SOUSEIKAI PS Clinic, Fukuoka, Japan, ²AstraZeneca K.K., Osaka, Japan, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Verinurad (RDEA3170) is a high-affinity URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, single-site study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].